Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

E-Prescription System Funding Transparency Recommended In Pfizer Study

This article was originally published in The Pink Sheet Daily

Executive Summary

Electronic prescribing systems should be designed to prevent the promotion of pharmaceuticals for non-clinical reasons, such as the benefit to third-party entities that may fund the system, a RAND expert panel suggests in a report commissioned by Pfizer.
Advertisement

Related Content

E-Prescribing Systems Should Provide Individualized Cost Data, Pfizer Says
E-Prescribing Systems Should Provide Individualized Cost Data, Pfizer Says
E-Prescribing Meeting By HHS Cmte. Set For May 25-27
E-Prescribing Meeting By HHS Cmte. Set For May 25-27

Topics

Advertisement
UsernamePublicRestriction

Register

PS059513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel